Cirmtuzumab, Ibrutinib Therapy Well Tolerated In Both CLL/MCL

ASCO 2021: Results of a study investigating cirmtuzumab combined with ibrutinib for treatment of relapsed chronic lymphocytic leukemia and mantle cell lymphoma.